Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > 10% drop for what

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jun 05, 2023 12:02pm

87 Views

Post# 35480523

RE:RE:RE:RE:RE:RE:RE:RE:10% drop for what

If Akero is putting up those numbers then it sure seems like any money we spent on NASH may have been wasted. It may turn out to be a blessing in disguise that NASH never went forward as it would be hard to compete with 65% fat reduction.

Trogarzon wrote: Always waiting... the art of can kicking. Also Akero is blasting past Egrifta like other competitors with 65% fat reduction vs 40% for our thing.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?